Gottschalk J, Jautzke G, Zimmer C, Cervós-Navarro J
Institute of Neuropathology, Free University of Berlin, Germany.
Clin Neuropathol. 1993 Mar-Apr;12(2):68-72.
Since some monoclonal anti-cytokeratin antibodies also react with glial tumors to a relatively high degree, an immunohistochemical study was performed to examine the reaction of 40 glial tumors and neuroepithelial tumors with glial differentiation to the monoclonal anti-epithelial non-cytokeratin antibodies HEA 125 and Ber EP4. Seven of these tumors were cytokeratin-positive neoplasms (6 gliosarcomas and 1 ependymoma). In addition, 20 metastatic carcinomas were investigated. All glial tumors showed a negative reaction to HEA 125 and Ber EP4, whereas 19 of the 20 metastatic carcinomas were positive with these two monoclonal antibodies. HEA 125 and Ber EP4 thus can be used as additional markers especially in cytokeratin-negative small cell carcinomas.
由于一些单克隆抗细胞角蛋白抗体也与神经胶质瘤有较高程度的反应，因此进行了一项免疫组织化学研究，以检测40例神经胶质瘤和具有神经胶质分化的神经上皮肿瘤对单克隆抗上皮非细胞角蛋白抗体HEA 125和Ber EP4的反应。这些肿瘤中有7例为细胞角蛋白阳性肿瘤（6例胶质肉瘤和1例室管膜瘤）。此外，还研究了20例转移性癌。所有神经胶质瘤对HEA 125和Ber EP4均呈阴性反应，而20例转移性癌中有19例对这两种单克隆抗体呈阳性反应。因此，HEA 125和Ber EP4尤其可作为细胞角蛋白阴性小细胞癌的辅助标志物。
